Catalyst Dossier · compiled by CeliA 🧫

Vericel Corporation (VCEL)

Biological Products, (No Diagnostic Substances) · market cap $2.0B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Vericel Corporation (VCEL) is a commercial-stage biologics company with 357 employees and a $2.3B market cap, built around MACI, an autologous chondrocyte implant for cartilage repair, which is already generating material revenue. The company has reached profitability on a net income basis as of 2025 ($17M net on $276M revenue) and carries a net cash position of $109M with no disclosed debt. The next scheduled catalyst is a Q2 2026 earnings release on July 30.

The catalyst path

2026-07-30Earningsimp 5/10

Pipeline

Asset	Phase	Indication
MACI	Phase 3	Chondral Defect
autologous cultured chondrocytes on porcine collagen membrane	Phase 3	Articular Cartilage Defect
ixmyelocel-T	Phase 3	Ischemic Dilated Cardiomyopathy (IDCM)

Price & technical context

3-month

+44.3%

6-month

+27.9%

12-month

+12.9%

52-wk range

$29.34–$46.98

vs 50-day MA

+27.3%

vs 200-day MA

+30.8%

Realized vol

49.8%

Max drawdown

-52.5%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VCEL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.